Core Viewpoint - Yongsheng Medical (01612) has experienced a stock price increase of over 9% following the announcement of a positive earnings forecast, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Group 1: Earnings Forecast - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Group 2: Reasons for Growth - The board attributes the significant increase in revenue to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross profit margins [1]

Core Viewpoint - Yongsheng Medical (01612) has issued a positive earnings forecast, leading to a stock price increase of over 9%, with the current price at 0.93 HKD and a trading volume of 5.704 million HKD [6]. Financial Performance - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than 100 million HKD for the fiscal year ending December 31, 2025, compared to an audited profit of approximately 69.2 million HKD for the fiscal year ending December 31, 2024 [6][1]. - The expected profit increase is attributed to strengthened relationships with a major customer in the imaging disposable products segment and business expansion, which significantly boosts revenue [6][1]. Operational Efficiency - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to an improved gross profit margin [6][1].

Core Viewpoint - Yongsheng Medical (01612) experienced a stock price increase of over 9% following a profit alert, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Financial Performance - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Business Drivers - The significant increase in revenue is attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross margins [1]

Core Viewpoint - Yongsheng Medical (01612.HK) expects to record an unaudited consolidated profit attributable to owners of no less than HKD 100 million for the year ending December 31, 2025, compared to an audited profit of approximately HKD 69.2 million for the year ending December 31, 2024 [1] Group 1 - The anticipated profit increase is primarily attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale, leading to a significant rise in revenue [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, which in turn has improved gross profit margins [1]

Core Viewpoint - Yongsheng Medical (01612) anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the year ending December 31, 2025, compared to an audited profit of approximately HKD 69.2 million for the year ending December 31, 2024 [1] Group 1 - The expected profit increase is primarily attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross margins [1]

2025年上半年表现强劲主要受成像一次性产品分部所得收入上升28.6%所带动。呼吸产品分部的收入回 复增长，幅度更足以抵销有余来自骨科支护复康器具分部贡献的减少。在规模经济效益扩大、营运效率 提升及存货拨备减少的因素支持下，毛利增加33.4%至159.0百万港元。毛利率由31.3%改善至35.4%。 格隆汇8月20日丨永胜医疗(01612.HK)公告，集团交出过去四年来最强劲的中期业绩，截至2025年6月30 日止6个月录得收入增长达18.1%至4.49亿港元。期间公司拥有人应占溢利增加55.1%至5160万港元。纯 利率升至12.1%(2024年上半年：8.8%)。每股盈利增加55.3%至8.03港仙(2024年上半年：5.17港仙)。贯 彻本公司的股息政策，董事会议决宣派本期间的中期股息每股2.4港仙(2024年上半年：1.6港仙)。 ...

2025年上半年表现强劲主要受成像一次性产品分部所得收入上升28.6%所带动。 永胜医疗(01612)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入4.49亿港元，同比增加 18.05%;公司拥有人应占溢利5162.9万港元，同比增加55.1%;基本每股盈利8.03港仙。 呼吸产品分部的收入回复增长，幅度更足以抵销有余来自骨科支护复康器具分部贡献的减少。 在规模经济效益扩大、营运效率提升及存货拨备减少的因素支持下，毛利增加33.4%至1.59亿港元。毛 利率由31.3%改善至35.4%。 ...

呼吸产品分部的收入回复增长，幅度更足以抵销有余来自骨科支护复康器具分部贡献的减少。 在规模经济效益扩大、营运效率提升及存货拨备减少的因素支持下，毛利增加33.4%至1.59亿港元。毛 利率由31.3%改善至35.4%。 智通财经APP讯，永胜医疗(01612)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入4.49亿 港元，同比增加18.05%;公司拥有人应占溢利5162.9万港元，同比增加55.1%;基本每股盈利8.03港仙。 2025年上半年表现强劲主要受成像一次性产品分部所得收入上升28.6%所带动。 ...